enGene Therapeutics
ENGN · NASDAQ
$1.67+$0.09 (+5.70%)TodayMarket closed ·
Prev close $1.58
EPS: actual vs estimate
Beat the estimate in 3 of the last 8 quarters, by 15.0% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q3 FY26 | -$0.4386 | -$0.47 | −7.2% |
| Q2 FY26 | -$0.4795 | -$0.43 | +10.3% |
| Q1 FY26 | -$0.571 | -$0.44 | +22.9% |
| Q4 FY25 | -$0.5796 | -$0.73 | −25.9% |
| Q3 FY25 | -$0.5111 | -$0.57 | −11.5% |
| Q2 FY25 | -$0.5081 | -$0.51 | −0.4% |
| Q1 FY25 | -$0.3787 | -$0.48 | −26.7% |
| Q4 FY24 | -$0.3852 | -$0.34 | +11.7% |
Earnings calls
- Special Call - enGene Therapeutics Inc.
- Morgan Stanley 24th Annual Global Healthcare Conference
- Special Call - enGene Therapeutics Inc.
- Special Call - enGene Therapeutics Inc.
- Barclays 28th Annual Global Healthcare Conference
- Special Call - enGene Holdings Inc.
- Morgan Stanley 23rd Annual Global Healthcare Conference
- Special Call - enGene Holdings Inc.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.